Lisata Therapeutics Q2 EPS $(0.50) Beats $(0.70) Estimate
Portfolio Pulse from bharat@benzinga.com
Lisata Therapeutics reported Q2 losses of $(0.50) per share, beating the analyst consensus estimate of $(0.70) by 28.57%. This is a 69.51% increase over losses of $(1.64) per share from the same period last year.
August 14, 2023 | 8:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lisata Therapeutics' Q2 losses were less than expected, which could be seen as a positive sign by investors.
Lisata Therapeutics reported lower than expected losses for Q2, which is generally seen as a positive sign by investors. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100